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Abstract
Background: Small cell carcinoma of the cervix (SCCC) is very rare, and due to the long time period required to recruit
sufficient numbers of patients, there is a paucity of information regarding the prognostic factors associated with survival.
MicroRNAs (miRNAs) have been used as cancer-related biomarkers in a variety of tumor types, and the objective of this
study was to determine whether microRNA expression profiles can predict clinical outcome in SCCC.
Methodology/Principal Findings: Forty-four patients with SCCC who underwent radical hysterectomy between January
2000 and October 2009 were enrolled. Using the GeneCopoeia All-in-One
TM Customized Human qPCR Primer Array, the
expression profiles of 30 miRNAs associated with tumor metastasis was obtained from the formalin-fixed paraffin
embedded samples of all 44 patients. Seven miRNAs, has-let-7c, has-miR-10b, has-miR-100, has-miR-125b, has-miR-143, has-
miR-145 and has-miR-199a-5p were significantly down-regulated in advanced stage SCCCpatients (FIGO IB2-IV) compared
to early stage SCCC patients (FIGOIB1). Among, downregulation of six miRNAs, has-let-7c, has-miR-100, has-miR-125b, has-
miR-143, has-miR-145 and has-miR-199a-5p were significantly associated with lymph node metastasis and reduced survival
in SCCC. Kaplan–Meier survival analyses revealed that SCCC patients with low expression of has-miR-100 (P=0.019) and has-
miR-125b (P=0.020) projected a significant tendency towards poorer prognosis.
Conclusions/Significance: This study demonstrates that downregulation of 7 miRNA associated with advanced stage, 6
miRNAs with metastasis and 2 with poor prognosis in SCCC. Functional analysis of these miRNAs may enhance our
understanding of SCCC, as altered expression of specific miRNAs may regulate the metastatic pathway and provide novel
targets for therapy.
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Introduction
Neuroendocrine small cell cervical carcinoma (SCCC) is an
aggressive, rare form of cervical cancer, accounting for less than
3% of all cervical cancers [1–3]. SCCC is characterized by a
high incidence of early nodal and distant metastases, resulting in
a poorer prognosis than other subtypes of cervical cancer [4–6].
Previous studies have reported that 60–82% of SCCC patients
have lymph-vascular space infiltration or pelvic lymph node
metastasis at diagnosis [7–9]. Additionally, SCCC exhibits a
propensity for rapid distant metastasis via the bloodstream to
various sites including the liver, lung, brain, bone, pancreas and
lymph nodes, which results in treatment failure in most cases [8–
11]. Recurrences usually occur within 2 years, and most patients
die as a result of early metastasis. It is important to identify the
factors responsible for the survival of metastases in order to
improve treatment strategies for SCCC. However, due the rarity
and the long time period required to enroll a sufficient number
of patients, most studies on SCCC are comprised of small series
or case reports, making it difficult to determine the optimal
therapy.
MicroRNAs (miRNAs) are noncoding RNAs 18 to 25
nucleotides in length [12]. The effects of miRNAs are mediated
by binding to target mRNAs, to either suppress mRNA translation
or degrade miRNA-bound mRNA [13]. Currently, more than
several hundred unique mature human miRNAs are known, and
many are involved in tumorigenesis, acting either as oncogenes
[14] or tumor suppressors [15,16]. Aberrant expression of
miRNAs has also been linked to cancer [17,18], suggesting that
miRNAs potentially represent prognostic markers, and leading to
the use of miRNA profiling for the diagnosis and prognosis of
specific cancers. It has been shown that miRNAs are involved in
every type of cancer examined to date; however, the expression of
miRNAs in SCCC has not been investigated.
PLoS ONE | www.plosone.org 1 March 2012 | Volume 7 | Issue 3 | e33762In this study, miRNA qPCR arrays were performed on 44
SCCC samples, as we hypothesized that investigation of miRNA
profiles would provide more information on SCCC, an inade-
quately understood disease with a poor prognosis.
Materials and Methods
Ethics Statement
All patients agreed to participate in the study and gave written
informed consent. This study was approved by the medical ethics
committee of Cancer Center of Sun Yat-Sen University and
complied with the Declaration of Helsinki.
Samples and Cases
Formalin-fixed paraffin-embedded tissues (FFPETs) from 44
SCCC patients undergoing radical hysterectomy between January
2000 and October 2009 were obtained from the Cancer Center,
Sun Yat-SenUniversity, Guangzhou, P.R.China. The patients had
not received any preoperative radiotherapy and/or chemotherapy,
and the SCCC diagnosis was confirmed by pathology. All patients
were staged according to the International Federation of
Gynecology and Obstetrics (FIGO) staging system for cervical
cancer.
MicroRNA extraction and reverse transcription
The Leica DMLA system (CTRMIC from Leica, Germany) was
used to microdissect the tumor cells and the stromal cells from the
FFPET sections. Ten sections were used to obtain sufficient RNA
for reverse transcription polymerase chain reaction (RT-PCR),
Processing of the total RNA began immediately following
microdissect. Total RNA was isolated using the miRNeasy FFPE
Kit (Qiagen, Hilden, Germany) according to the manufacturer’s
instructions, and the quality and concentration of RNA was
determined using a Nanodrop 1000 (Thermo, Wilmington, DE,
USA). MicroRNAs were isolated from total RNA using the All-in-
One
TM miRNA qRT-PCR Detection Kit (GeneCopoeia, Rock-
ville, Md, USA), according to the manufacturer’s instructions, by
reverse-transcription of mature miRNAs using Poly-A polymerase
with an oligo-dT adaptor.
MicroRNA qPCR Array
The All-in-One
TM Customized Human qPCR Primer Array
(HAQPA-1103-01-24D; GeneCopoeia Inc, Rockville, Md, USA)
96-well-qPCR plate was used for this study. Each array is a panel
of validated, optimized qPCR primers for 30 miRNAs closely
associated with tumor metastasis, and the housekeeping genes
RNU6B and SNORD44, which are used as reference factors to
normalize the expression results. Each well contains a forward
primer for the mature miRNA sequence and a universal adaptor
reverse primer cross-linked to the 96-well plate. The qPCR
Primer Array was performed in 20 ml reaction volumes
containing 1 ml reverse transcription product, according to the
manufacturer’s instructions using SYBR Green detection on the
ABI 7900HT instrument (Applied Biosystems, Carlsbad, CA,
USA).
Confirmed all PCR products by sequencing
TA clone was performed according to the protocols with minor
modifications of TOPO TA Cloneing Kit for sequencing
(Invitrogen). Briefly, purify the PCR products with PCR products
purification kit (QIAGEN) first. Then pool 1 ml TA vector
(TOPO-TA cloning kit, Invitrogen), 1 ml1 0 6_ ligation buffer,
5 ml PCR products, 1 ml Ligase into one tube and add water to
make the final volume 10 ml, Ligate at 14_ overnight. The next
day, Combine one tube of One-Shot TOP10 competent cells
(Invitrogen) with 2 ml of the previous ligation products and use X-
gal/IPTG to screen white colonies as colonies with insert. Final,
pick up 10 white colonies to make plasmid DNA and sent to
Invitrogen (Guangzhou, China) for DNA sequencing.
Follow-Up
The patients were followed every 3 months for the first year and
then every 6 months for the next 2 years and finally annually,
thereafter. The total follow-up period was defined as the time from
diagnosis to the date of death or the last date censused if patients
were still alive. Censoring refers to the patients who did not
diagnosis in our hospital and can not provide actual diagnose time.
There are all 42 patients that is included in survival data analysis.
The last follow-up was carried out in December 2010, with a mean
observation period of 23.6 months (range: 2–70 months) and 13
cancer-related deaths.
Statistical Analysis
The miRNA expression levels were analyzed using the GeneCo-
poeia online Data Analysis System (www.genecopoeia.com.cn/
product/qpcr/analyse/). Using the relative quantification (RQ)
equation, where DDCT=(CTmiRNA2CTRNU6B+SNORD44/2)M e a n
metastasis2(CTmiRNA2CTRNU6B+SNORD44/2)M e a nno-metastasis).
Cluster analysis was performed using the MultiExperiment Viewer
4.2 software (http://mev.tm4.org). Statistical analysis was carried
out using SPSS Version 13.0 (SPSS Inc., Chicago, IL, USA).
Survival curves were estimated by the Kaplan–Meier method, and
compared using the log-rank test. Parameters that were significantly
related to survival in univariate analysis were entered into the
multivariate analysis. With a Cox proportional hazard model,
multivariate analysis was done to identify the independent
prognostic factors. Receiver operating characteristic (ROC) curve
analysis was employed to determine whether the miRNAs found are
really good candidates to discriminate early from advanced tumour
stagesand presenceorabsence oflymph node metastasis. Two-sided
P values,0.05 were considered significant.
Results
Clinicopathological Features
The forty-four patients ranged in age from 24 to 66 years with a
median age of 41 years. At the time of surgery, 18 patients (40.9%,
18/44) were classified as stage IB1, 12 (27.3%, 12/44) as stage
IB2, 6 (13.6%, 6/44) as stage IIA, 5 (11.4%, 5/44) as stage IIB, 2
(4.5%, 2/44) as stage III and 1 (2.3%, 1/44) as stage IV. Lymph
node involvement was present in 14 (31.8%, 14/44) patients at the
time of surgery. During the follow-up period, 19 (43.1%, 19/44)
patients presented disease recurrence and 13 (29.5%, 13/44)
patients died of cervical cancer. The clinicopathological charac-
teristics of the 44 SCCC patients are shown in Table S1.
Reliability of miRNA Detection in FFPET Samples by the
All-in-One
TM Customized Human qPCR Primer Array
Each primer set cross-linked to the All-in-One qPCR Primer
Array was validated to amplify a single product of the correct size
for each target gene from microRNAs isolated from human
formalin-fixed paraffin-embedded and frozen cervix tissue
(Figure 1A). The peak values of the amplification and melting
curves indicated a single amplificationproduct was obtained in each
reaction (data not shown). A significant correlation was observed in
the miRNA expression pattern of plat1 (SCCC FFPET sample 1,
sample 2, sample 3) and plat2 (SCCC FFPET sample 1, sample 2,
sample 3), with an R
2 value of 0.943(Figure 1B). In addition, all
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(Figure 2).Taken together, these results indicate that the All-in-
One
TM Customized Human qPCR Primer Array has a high
specificity and sensitivity to detect miRNA expression levels in
SCCC FFPET samples, with a high degree of reproducibility.
Differentially Expressed miRNAs are Associated with
Advanced Tumor Stage and Lymph Node Metastasis in
SCCC Specimens
From the 44 SCCC cases, FIGOI-IIA samples were combined
as an early stage SCCC group and FIGOIIB-IV samples as an
advanced stage SCCC group. Using the GeneCopoeia online
Data Analysis System, we identified 9 miRNAs which could
significantly discriminate between tumor tissues from the ad-
vanced stage SCCC group and early stage SCCC group (P,0.05,
Table S2). Has-let-7c, has-miR-10b, has-miR-100, has-miR-
125b, has-miR-143, has-miR-145 and has-miR-199a-5p were
significantly down- regulated in advanced stage SCCC, compared
to early stage SCCC. Unsupervised hierarchical cluster analysis of
the nine differentially expressed miRNAs in all 44 SCCC samples
(Figure 3) created two major cluster branches, one of which
included mainly advanced stage SCCC samples and the other
included mainly early stage SCCC samples.
We also identified nine miRNAs (has-let-7c, has-miR-31, has-
miR-100, has-miR-125b, has-miR-143, has-miR-145, has-miR-
199a-5p, has-miR-203 and has-miR-218) which could significantly
discriminate between tumor tissues from patients with metastasis
(M, n=13) and without metastasis (NM, n=31, P,0.05).
Interestingly, of the nine miRNAs associated with metastasis,
downregulation of has-let-7c, has-miR-100, has-miR-125b, has-
miR-143, has-miR-145 and has-miR-199a-5p were also signifi-
cantly correlated with advanced tumor stage as described above.
Figure 1. Validation of the All-in-One
TM Customized Human qPCR Primer Array detection system. (A) Amplification of 30 miRNAs (P1-
P30, see Table S2; P24-P30 and SNORD44 are not show in this figure because of limit lane on a single agarose gel; lane1: FFPET human cervix, lane2:
frozen human cervix, lane3: RT-minus control and lane4: negative control for each miRNA) and two reference genes (RNU6B, SNORD44) from cDNA
synthesized from human cervix total RNA. All qPCR products were detected by electrophoresis on a 2.5% agarose gel, indicating a single product of
the correct size for each target gene. (B) A significant correlation between the miRNA expression patterns in cDNA synthesized from formalin-fixed
paraffin-embedded small cell carcinoma of the cervix samples (plat1: sample 1, sample 2, sample 3 and plat2: sample 1, sample 2, sample 3) was
observed, R
2=0.943, demonstrating a high reproducibility and reliable detection of miRNA expression levels.
doi:10.1371/journal.pone.0033762.g001
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Patient Survival
Kaplan–Meier survival analyses revealed that the SCCC
patients with low expression of has-miR-100 (P=0.019) and has-
miR-125b (P=0.020) had a poorer prognosis compared to
patients with high expression of these miRNAs, while has-let-7c
(P=0.071), has-miR-143 (P=0.064), has-miR-145 (P=0.072) and
has-miR-199a-5p (P=0.056) down-regulation tended to adversely
affect survival. However, these findings were not statistically
significant (Figure 4). Since variables observed to have prognostic
influence by univariate analysis may covariate, the downregulation
of has-miR-100, has-miR-125b as well as FIGO stage that were
Figure 2. All PCR amplification products were confirmed by sequencing. (A): representative chromas of the 30 miRNAs. (B): the result of
sequencing for each miRNAs.
doi:10.1371/journal.pone.0033762.g002
Figure 3. Unsupervised hierarchical cluster analysis of nine differentially expressed miRNAs in 44 samples of advanced and early
stage small cell carcinoma of the cervix. Each row represents an individual miRNA and each column represents an individual tissue sample. Two
major cluster branches were created, one including mainly advanced tumor stage samples and the other including mainly early tumor stage samples.
Red, black, and green pseudocolors indicate transcripts levels below, equal, or above the mean, respectively, on a scale representing gene expression
ratios from 23 to 3 on a log 2 scale.
doi:10.1371/journal.pone.0033762.g003
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analysis (Table S1). We found that downregulation of has-miR-
100 was evaluated as an independent risk factor for patient
survival (hazards ratio: 0.161; 95% confidence interval: 0.036–
0.814; P=0.044). Of the other variables, FIGO stage also was
found to be independent prognostic predictors for overall survival
(Table S1).
Receiver operating characteristic (ROC) curve analysis
ROC curve analysis showed that the miRNAs found in this
study are good candidates to discriminate early from advanced
tumour stages and presence or absence of lymph node metastasis.
The sensitivity and specificity of discriminate early from advanced
tumour stages for each miRNA were plotted: has-let-7c
(P=0.009), has-miR-100 (P=0.002), has-miR-125b (P=0.003),
has-miR-143 (P=0.006), has-miR-145 (P=0.004), has-miR-199a-
5p (P=0.015). Similarly, the sensitivity and specificity of
discriminate presence or absence of lymph node metastasis for
each miRNA were: has-let-7c (P=0.030, has-miR-100 (P=0.025),
has-miR-125b (P=0.007), has-miR-143 (P=0.016), has-miR-145
(P=0.009), has-miR-199a-5p (P=0.008). The corresponding area
under the curve (AUC) was collected and shown in Figure 5 and
Figure 6.
Discussion
Small cell carcinoma of the uterine cervix is an uncommon
malignancy, accounting for 0.5–3% of all cervical cancers. Similar
to lung small cell cancer, SCCC is difficult to manage and usually
follows an aggressive clinical course, with death occurring a few
years after diagnosis. During the follow-up period of this study, 19
(43.1%) patients presented disease recurrence and 13 (29.5%)
patients died. The Gynecologic Oncology Group attempted to
study SCCC, but failed to recruit a sufficient number of patients.
As a result, treatment decisions in SCCC are based on small single
institution studies, and have extrapolated treatment approaches
from the management of small cell cancer of the lung. The
prognosis of SCCC is considered to be similarly poor to small cell
cancer of the lung; however, long-term survival has been reported
in SCCC patients [19–21]. To determine whether microRNA
Figure 4. Kaplan-Meier estimates of overall survival in 44 patients with stage small cell carcinoma of the cervix according to has-
let-7c (A), has-miR-100 (B), has-miR-125b (C), has-miR-143 (D), has-miR-145 (E) andas-miR-199a-5p expression (F). Has-miR-100 and
has-miR-125b down-regulation were significantly associated with poorer survival, and has-let-7c, has-miR-143, has-miR-145 and has-miR-199a-5p
down-regulation tended to predict poorer survival, although these results were not statistically significant.
doi:10.1371/journal.pone.0033762.g004
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total of 44 patients with small cell carcinoma of the cervix were
enrolled in this study. Using real-time RT-PCR, we quantified the
microRNA expression in FFPET samples of all 44 SCCC patients,
and to our knowledge, this is the first attempt to study microRNA
molecular markers in SCCC.
Nelson et al. first reported that miRNAs could be isolated and
profiled from FFPET samples [22], and subsequently, many
studies have reported that small RNA molecules are only slightly
affected by tissue processing and that miRNAs demonstrate stable
expression in FFPET samples [23]. Our results confirm that
miRNAs can be reliably detected in total RNA isolated from
SCCC FFPET samples using real-time RT-PCR. The qPCR
Primer Array used in this study combines the advantages of real-
time RT-PCR technology with a microchip platform to allow
simultaneous detection of many genes, ensuring fast, sensitive,
quantitative results to allow rapid and accurate screening of
interesting genes for further study.
In this study, we observed that downregulation of six miRNAs
(has-let-7c, has-miR-100, has-miR-125b, has-miR-143, has-miR-
145 and has-miR-199a-5p) is associated withadvanced tumor stage,
lymph node metastasis and poorer survival in SCCC patients
(Table 1), suggesting that clustering analysis based on miRNA
expression may facilitate a detailed individual diagnosis of SCCC
patients. Downregulation of miR-143 and 145 are also observed in
other tumor types including breast, gastric, liver, lung, bladder,
pituitary, ovary and colon cancer [24–31]. Several miR-143 targets,
including DNMT3A and KRAS [32,33], and miR-145 targets
including BNIP3, IRS, C-MYC, YES and STAT1 [34–36], have
been identified, indicating that miR-143 and 145 act as tumor
suppressors to repress tumor proliferation or promote apoptosis.
Recently,altered processing of miR-143 and 145 had been linkedto
metastasis [37–39], and our study suggests that down-regulation of
miR-143 and 145 may also promote lymph node metastasis in
SCCC. Sachdeva et al. observed that miR-145 targets multiple
metastasis-related genes including MMP-11 and ADAM-17 [40],
which may potentially contribute to increased metastasis in SCCC.
MiR-199a is downregulated in lung cancer and is suggested to
be candidate tumor suppressor [41]. Shen et al. reported that
decreased expression of miR-199a-5p contributes to increased cell
invasion by functional deregulation of DDR1 activity in hepato-
cellular carcinoma [42]. Recently, Hou, et al. observed that miR-
199a is frequently downregulated in hepatocellular carcinoma,
and that the degree of downregulation significantly correlated with
survival, indicating that miR-199a has potential as marker of
prognosis in hepatocellular carcinoma [43]. In our study, MiR-
199a was downregulated in the SCCC patients with lymph node
metastasis compared to patients without metastasis (fold change:
Figure 5. Receiver operating characteristic curve analysis was employed to determine whether the miRNAs found are really good
candidates to discriminate early from advanced tumour stages. The sensitivity and specificity for each miRNA were plotted: (A) has-let-7c
(P=0.009); (B) has-miR-100 (P=0.002); (C) has-miR-125b (P=0.003); (D) has-miR-143 (P=0.006); (E) has-miR-145 (P=0.004); (F) has-miR-199a-5p
(P=0.015).
doi:10.1371/journal.pone.0033762.g005
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has been associated with poorer survival in several other tumor
types, including acute myeloid leukemia and lung cancer [41,44],
suggesting that the role of miR-199a is dependent on the cell type.
Alternatively, cancer cells may produce miR-199a to promote cell
migration and invasion, and miR-199a could be downregulated
after metastasis. Further study is required to clarify the role of
miR-199a in SCCC. As several other miRNAs, including has-let-
7c, has-miR-100 and has-miR-125b are also downregulated in
SCCC, we aim to determine whether detection and analysis of
combined miRNA profiles can determine the prognosis of SCCC
patients more precisely in future studies.
Figure 6. Receiver operating characteristic curve analysis was employed to determine whether the miRNAs found are really good
candidates to discriminate the presence or absence of lymph node metastasis. The sensitivity and specificity for each miRNA were plotted:
(A) has-let-7c (P=0.030); (B) has-miR-100 (P=0.025); (C) has-miR-125b (P=0.007); (D) has-miR-143 (P=0.016); (E) has-miR-145 (P=0.009); (F) has-miR-
199a-5p (P=0.008).
doi:10.1371/journal.pone.0033762.g006
Table 1. Summary of the Associations of Six miRNAs with Advanced Tumor Stage, Lymph Node Metastasis, and Poor Survival in
Small Cell Carcinoma of the Cervix.
miRNA Expressed Tumor-related Host Targets
has-let-7c down lung and cervical cancer HMGA2
has-miR-100 down myeloid leukemia,cervical and prostate cancer RPSP3,PLK1
has-miR-125b down breast and colorectal cancer BAK1
has-miR-143 down rectal,colon, liver and lung cancer,
leukemia, osteosarcoma
BCL-2,KRAS, DNMT3A
has-miR-145 down gastric,breast and colon cancer BNIP3,IRS,STAT1
squamous cell cancer,bladder tumor YES,C-MYC
has-miR-199a-5p down esophageal adenocarcinoma,testicular tumor, hepatocellular and lung cancer SWI,SNF,PAK4
Data derived from the NCBI database (http://www.ncbi.nlm.nih.gov/pubmed/).
doi:10.1371/journal.pone.0033762.t001
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PLoS ONE | www.plosone.org 7 March 2012 | Volume 7 | Issue 3 | e33762In conclusion, this study has revealed that downregulation of
has-let-7c, has-miR-100, has-miR-125b, has-miR-143, has-miR-
145 and has-miR-199a-5p are significantly correlated with
advanced tumor stage, lymph node metastasis and poorer survival
in SCCC. Identification of altered expression of specific miRNAs
may further elucidate the steps in the SCCC metastatic pathway
and allow for development of novel targeted therapies. Although
this study has a simple design and is limited by the small numbers
of patients, it is the largest series of SCCC patients reported to
date. We hope that identification of the microRNA profile in SCC
contributes to an improved diagnostic and prognostic ability for
this rare and aggressive tumor.
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